Proxy Results (Form 8-K)

Item 5.07 Submission of Matters to a Vote of Security Holders.

Solid Biosciences Inc. (the "Company") held its Annual Meeting of Stockholders (the "Annual Meeting") on June 10, 2026 to consider and vote upon the matters listed below. The following is a summary of the matters voted on at the Annual Meeting.

1. The Company's stockholders elected Clare Kahn, Adam Stone and Lynne Sullivan as Class II directors to serve until the 2029 Annual Meeting of Stockholders, each director to hold office until his or her successor has been duly appointed and qualified. The results of the stockholders' vote with respect to the election of such Class II directors were as follows:

2. The Company's stockholders ratified the appointment of Ilan Ganot, on an advisory basis, as a Class I director to serve until the 2028 Annual Meeting of Stockholders. The results of the stockholders' vote with respect to such ratification were as follows:

3. The Company's stockholders ratified the appointment of PricewaterhouseCoopers LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2026. The results of the stockholders' vote with respect to such ratification were as follows:

4. The Company's stockholders approved an amendment to the Company's Certificate of Incorporation, as amended, to increase the number of authorized shares of the Company's common stock from 240,000,000 to 480,000,000 (the "Share Increase Amendment"). The results of the stockholders' vote with respect to such approval were as follows:

The Company filed a Certificate of Amendment to Certificate of Incorporation with the Secretary of State of the State of Delaware on June 10, 2026 to effect the Share Increase Amendment.

5. The Company's stockholders approved the non-binding, advisory vote on the compensation paid to its named executive officers. The results of the stockholders' vote with respect to such approval were as follows: